Researchers find that many Huntington disease specialist clinics do not have the resources available to administer DMTs appropriately with an intrathecal strategy.
Researchers found emotional issues, fatigue, and difficulties in thinking represent common symptomatic themes in patients with Huntington disease.
In patients with Huntington disease, higher levels of functional impairment and current alcohol consumption were significantly correlated with missing work in multivariate logistic regression analyses.
The Movement Disorder Society Task Force recently published a proposal for new diagnostic criteria for 3 Huntington disease categories.
The vast majority of people at risk for Huntington disease (HD) choose not to be tested preemptively, mainly because there is no cure for the disease.
Antisense oligonucleotide drug HTTRx reduced the concentration of mutant huntingtin protein in the cerebrospinal fluid of persons with Huntington disease.
Researchers sought to identify variables that were associated with suicidal ideation or behavior in patients with Huntington disease.
Investigators sought to assess factors contributing to progression of functional, cognitive, and motor impairment in Huntington disease.
Measurement of the disease protein huntingtin in saliva may be promising as an accessible, noninvasive biomarker to predict symptom severity and disease course in individuals with Huntington disease.
Researchers found that high doses of the novel antisense oligonucleotide were associated with lower concentrations of mutant huntingtin protein in the cerebrospinal fluid and brain.
